Oncternal Revenue and Competitors
Estimated Revenue & Valuation
- Oncternal's estimated annual revenue is currently $4.5M per year.
- Oncternal's estimated revenue per employee is $263,529
Employee Data
- Oncternal has 17 Employees.
- Oncternal grew their employee count by -53% last year.
Oncternal's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | SVP Corporate Development | Reveal Email/Phone |
3 | VP, Technical Operations & Alliance Management | Reveal Email/Phone |
4 | SVP, Regulatory Affairs and Quality | Reveal Email/Phone |
5 | Head Information Technology | Reveal Email/Phone |
6 | Head Biometrics & Data Sciences | Reveal Email/Phone |
7 | General Counsel & Corporate Secretary | Reveal Email/Phone |
8 | SVP, HR | Reveal Email/Phone |
9 | General Counsel | Reveal Email/Phone |
10 | VP, Clinical Development | Reveal Email/Phone |
Oncternal Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $212.8M | 1063 | 5% | $65M | N/A |
#2 | $35.6M | 247 | 18% | N/A | N/A |
#3 | $45M | 299 | -4% | $102.6M | N/A |
#4 | $3.2M | 30 | -25% | $21.3M | N/A |
#5 | $34M | 226 | 0% | $42.9M | N/A |
#6 | $3.6M | 34 | -28% | $35M | N/A |
#7 | $0.8M | 10 | N/A | N/A | N/A |
#8 | $12.6M | 90 | -9% | N/A | N/A |
#9 | $17.4M | 124 | 0% | $96.4M | N/A |
#10 | $5.2M | 49 | -25% | $75.6M | N/A |
What Is Oncternal?
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
keywords:N/A
N/A
Total Funding
17
Number of Employees
$4.5M
Revenue (est)
-53%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oncternal News
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle...
Oncternal Therapeutics Inc. said it has deprioritized development of its potential Ewing sarcoma treatment, ONCT-216, to reallocate...
Oncternal will reallocate resources to its global phase 3 study of its investigational anti-ROR1 monoclonal antibody zilovertamab for the...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.4M | 17 | -11% | N/A |
#2 | $0.8M | 17 | 6% | $21.4M |
#3 | $3.6M | 17 | N/A | N/A |
#4 | $1.5M | 17 | N/A | N/A |
#5 | $1.5M | 17 | N/A | N/A |